Nanoparticles for cancer therapy and imaging are designed to accumulate in the diseased tissue by exploiting the Enhanced Permeability and Retention (EPR) effect. This limits their size to about 100 nm. Here, using intravital microscopy and elemental analysis, we compare the in vivo localization of particles with different geometries and demonstrate that plateloid particles preferentially accumulate within the tumor vasculature at unprecedented levels, independent of the EPR effect. In melanoma-bearing mice, 1000× 400 nm plateloid particles adhered to the tumor vasculature at about 5% and 10% of the injected dose per gram organ (ID/g) for untargeted and RGD-targeted particles respectively, and exhibited the highest tumor-to-liver accumulation ratios (0.22 and 0.35). Smaller and larger plateloid particles, as well as cylindroid particles, were more extensively sequestered by the liver, spleen, and lungs. Plateloid particles appeared well-suited for taking advantage of hydrodynamic forces and interfacial interactions required for efficient tumoritropic accumulation, even without using specific targeting ligands.
Introduction
Many classes of nanoparticles (NPs) have been developed for diverse applications and some have shown potential in the treatment and imaging of diseases [1] [2] [3] [4] . Drug encapsulation into NPs can provide significant improvements in pharmacokinetics, toxicity and biodistribution compared to freely administered molecules. Indeed, NP formulations of chemotherapeutic agents have increased by one to two orders of magnitude the peak drug accumulation in tumors [5] , however, tumoritropic accumulation rarely exceeds 1% ID/g.
In cancer treatment and imaging, the commonly used strategy for maximizing NP accumulation relies on the enhanced permeation and retention (EPR) effect demonstrated by Maeda and collaborators 25 years ago [6, 7] . The tumor vasculature is discontinuous with vessel openings (fenestrations) whose size depends on the tumor type, stage and location [8] [9] [10] . Sufficiently small NPs (~100 nm) can passively exit the fenestrated vasculature and reach peak accumulation generally 12-24 h after injection. Curiously enough, major RES organs, such as the liver and spleen, are characterized by a fenestrated endothelium and utilize this same mechanism to sequester circulating foreign objects. Not surprisingly, a large portion of systemically injected agents and NPs end up accumulating in these RES organs.
Given the NP size limitation introduced by the EPR effect [9] [10] [11] [12] [13] , efforts to enhance tumoritropic accumulation to-date have mostly focused on the chemical modification of the particle surface. Examples include steric stabilization to increase NP circulation time (passive targeting) [5, 14] , conjugation of ligands for cell-specific recognition (active targeting) [15] [16] [17] , and active NP recruitment using endogenous [18] [19] [20] and exogenous [21, 22] sources (cooperative targeting). Nevertheless, NP accumulation at the intended target is still lower than desired. A judicious choice of the size, shape, and surface combinations, unrelated to the EPR effect, would offer extra degrees of freedom for optimizing tumoritropic accumulation.
Blood presents brilliant examples of how different size, shape, and surface combinations can provide circulating objects with diverse functions. For instance, healthy red blood cells (RBCs) can continuously navigate the circulatory system for several weeks while delivering oxygen. The size, shape, and physiochemical properties of the RBC membrane allow these cells to avoid entrapment within the complex microvasculature and, in larger vessels, to repel from the endothelial walls and preferentially stay within the vessel center [23, 24] . Conversely, platelets are mostly found in close proximity to the vessel walls, where they can periodically sense for and adhere to sites of vascular injury. This characteristic platelet behavior is ascribed to their small size (3 × smaller than RBCs) and quasi-discoidal shape [25, 26] .
Inspired by these phenomena, we reasoned that plateloid particlesthin disc-like particles -can be used for rapid, efficient, and specific accumulation within the tumor vasculature. Here, we fabricate nanoporous silicon particles with different geometries (size and shape) and surface properties; we monitor in real-time their dynamics using intravital microscopy and quantify, independently, their tissue accumulation by elemental analysis; and we interpret the in vivo data, using in silico mathematical modeling and in vitro adhesion assays, to elucidate the fine mechanisms regulating tumoritropic and RES accumulation.
Materials and methods

Animal models
Transgenic Tie2-GFP mice, engineered to express GFP in endothelial cells, were purchased from Jackson Labs (Bar Harbor, ME). The abdominal organs were exposed for intravital imaging via a 1.0 cm midline incision in the abdomen or flank. Melanoma tumors were generated in wild-type C57BL/6J mice (Charles River Laboratories, Wilmington, MA) by a one-time subcutaneous injection of 10 6 mouse B16 cells (ATCC, Manassas, VA). When tumors reached 3-5 mm in diameter, they were prepared for intravital imaging using a skin-flap procedure. Mice received a one-time injection of fluorescently labeled autologous red blood cells (RBCs) 1-3 days prior to imaging, in order to allow visualization of blood flow dynamics. Briefly, blood collected retro-orbitally was stained with lipophilic carbocyanine DiD (Invitrogen, Carlsbad, CA) at 37°C using the manufacturer's recommended protocol and immediately re-injected behind the contra-lateral eye. Approximately 5% of the total RBCs were labeled per mouse. Thirty minutes after particle injection, mice were sacrificed by gravity perfusion with saline followed by 10% neutral buffered formalin. All intravital animal protocols were reviewed and approved by the IACUC at Massachusetts General Hospital.
Intravital image acquisition and analysis
Organ-specific accumulation of plateloid silicon particles in vivo was monitored in real-time using a custom, video-rate laser scanning confocal microscope equipped with an x-axis polygon scanner, y-axis galvanometer, 3 lasers (491, 532, and 635 nm), and 3 photomultiplier tubes [34, 35] (Supplementary Information). Band pass filters of 30-35 nm width were centered at 425 nm (GFP), 579 nm (particles), and 670 nm (red blood cells). Anesthetized, surgically opened mice were positioned upon the heated stage and injected retro-orbitally with 5 × 10 8 particles of a single size (in 50 μl PBS). Three-channel images were acquired from a single organ per animal at 30 frames per second from the time of injection using a 40 × 0.6 NA dry objective with a pinhole of 100 μm. To minimize local phototoxicity and compensate for tissue heterogeneity, randomly selected non-overlapping regions of interest (ROI, 250 × 250 × 6 μm) were imaged continuously for 3 min before moving to the next ROI. Animals were imaged for 30 min and then sacrificed as described above. A total of 4-8 organs/particle/ strain were imaged in real-time. To determine particle accumulation as a function of time, the number of particles per field of view (FOV) was estimated from video stills at 10-second intervals using ImageJ v1.34 (NIH, Bethesda, MD). The 8-bit images were split by color, single pixel noise was removed using a minimum noise filter, and then the total number pixels above a threshold intensity of 50 was divided by the average number pixels per particle. The average number of pixels per particle was experimentally determined for each particle size and confirmed by comparing manual particle counts to automated particle counts. The number of particles per FOV was divided by the optical imaging volume and plotted as a function of time. Representative raw IVM images and quantitative data is shown in Supplementary Fig. 9 .
Particle fabrication and conjugation
Porous silicon particles were fabricated by modification of previously described protocols [33] , as detailed in the Supplementary Information. Images (Supplementary Fig. 8 ) and characterization data (Supplementary Table 1 ) are also provided.
2.4. The probability of particle adhesion to the vascular walls At time t = 0, the particle is in close proximity of the vessel wall with all potential ligand-receptor bonds still open (no adhesion). With time, ligands and receptors interact and tend to form molecular bonds with a probability p n (t) of having n bonds close at time t governed by the equation [52] 
where k f (n) (t) and k r (n) (t) are the forward (association) and reverse (dissociation) rates at time t for n close bonds. A c is the area of adhesion which is given by πd 2 for a plateloid particle with diameter d). Assuming for simplicity a uniform distribution of the hydrodynamic dislodging forces over the n molecular bonds at each time t, the reactions rates take the explicit forms
where χ (=0.1 nm) is the characteristic bond length, and k B T is the Boltzmann thermal energy (=4.14 × 10 − 21 J). k fo and k ro are the forward and reverse rates at zero mechanical load, and their ratio k ao (=k fo /k ro ) is the ligand-receptor affinity at zero mechanical load. The ligand-receptor bond density m b is equal to the minimum value between m r and m l . Eq. (2) . The probability of adhesion P a is defined as the probability of having at least one ligand-receptor bond close and is easily estimated as P a (t)=1 p o (t). The generalized force F exerted over the adhering plateloid particle are estimated, following previous work [53] , as F = πAμSa 2 , where S is the wall shear rate, μ is the plasma viscosity (2.5 × 10 − 3 Pa × s), and the coefficient A depends on the aspect ratio b/a, which is~0.35 in the present analysis.
Results and discussion
Nanoporous silicon plateloids and cylindroids
Precise control over multiple scales of the NP size, shape, and surface properties is reliably achieved with few technologies [27] [28] [29] [30] . Nanoporous silicon particles were chosen for these studies due to their documented advantages in the treatment and imaging of tumors [31] [32] [33] [34] [35] . Particles of different geometries were fabricated using two consecutive steps: formation of a porous silicon film and micropatterning. The particle porosity and pore size were tailored by electrochemical etching, controlling parameters such as silicon doping, etching current, and HF concentration; while the particle size was precisely defined by photolithography. Since the pore structure and particle geometry are independently controlled, a wide range of size, shape and pore morphologies can be reliably achieved with such an approach [36] . Three sizes of plateloid particles with similar aspect ratios were fabricated: 600 × 200 nm, 1000 × 400 nm, and 1800 × 600 nm. Two sizes of cylindroid particles were fabricated: 1500 × 200 nm and 1800 × 400 nm, which exhibit a volume equivalent to that of the two smaller plateloid particles. Fig. 1a shows SEM images of plateloid and cylindroid particles before and after release from the original silicon wafer.
Particles of plateloid and cylindroid shape are expected to exhibit fairly complex dynamics under flow and will tend to drift laterally across the stream lines in a periodic manner (Fig. 1b -Margination  inset) . Particle interaction with the vessel walls is a critical step for the recognition of the diseased vasculature. In silico mathematical models have shown that lateral drifting diminishes as the NP size decreases, becoming irrelevant for particles of~100 nm or less [37] . Also, moving from spherical to anisometric particles increases lateral drifting, as well as the probability of firm vascular adhesion because of the larger surface area exposed to the endothelial wall [38] ( Fig. 1b -Adhesion inset) . Sub-micrometer and micrometer anisometric particles offer the further advantage of a high cargo capacity, allowing for the localized release of therapeutic and imaging agents at the site of vascular adhesion (Fig. 1b -Release inset) .
The nanoporous silicon particles were labeled with fluorescent dye molecules for optical tracking within the blood flow. Their dynamics was monitored in live mice following systemic injection using high-resolution, video-rate intravital microscopy (IVM) [39, 40] . Fig. 1c captures some of the distinctive features exhibited by individual particles within the microvasculature, including differential transport velocities and adhesion to the vessel walls.
Particle localization at the organ scale
To evaluate the importance of particle geometry (size and shape) for organ accumulation, the biodistribution of individual particles was examined (Fig. 2) . Fig. 2a shows representative images of particle accumulation in different organs, collected in vivo 1 h after injection. Videos of particle accumulation and additional images are provided in the supplementary information (Supplementary Figs. S1 and S2, and Supplementary Movies 1 and 2). This IVM technique was used, for the first time, to quantify the time-dependent accumulation of the particles in live mice (Fig. 2a) . Fig. 2b shows the accumulation of 600 × 200 and 1000 × 400 nm plateloid particles in three different organs of wild-type, melanoma-bearing mice. Unlike EPR-based delivery strategies, the accumulation of these particles was most rapid for the first 5-10 min after injection, and then began to level off. Note that, in the liver and spleen, 600 × 200 plateloid particles accumulated faster and in greater numbers (~3×) than the 1000 × 400 nm. This trend was reversed in tumor tissue (~1/4×). The cumulative particle uptake measured by IVM is shown in Fig. 3a , where the effect of particle geometry can be readily appreciated.
Using ICP-AES, the total number of accumulated particles was independently quantified in whole organs after animal sacrifice. The particle biodistribution, expressed in terms of percentage of the injected dose normalized by the organ weight, shows that geometry (size and shape) plays a significant role in the ability of NPs to preferentially accumulate in different tissues (Fig. 3b) . In liver and spleen, 600 × 200 nm plateloid particles display the highest accumulation efficiency. In contrast, cylindroid particles accumulate at much higher levels than plateloid particles in the lungs. Most interestingly, in the tumor, 1000 × 400 nm plateloid particles demonstrate the highest accumulation efficiency of all particles examined (5% ID/g tumor). The trends observed in the IVM data (Fig. 3a) and ICP-AES data (Fig. 3b,  Supplementary Fig. 3 ) are in good qualitative agreement.
Several of the animals receiving cylindroid particles died spontaneously between 30 and 60 min after injection, showing signs of labored breathing before death and gross signs of lung emboli upon necropsy. It is possible that these rigid cylindroid particles have a similar capacity for causing lung emboli as the so called 'ugly' nanotubes [41]. Shorter cylindroid particles may provide different biodistributions, but also much lower payloads due to their smaller volume. Since no complications were observed with plateloid particles, these were used for assessing the importance of molecular targeting in tumors.
Fluorescently tagged plateloid particles were derivatized with a cyclic arginine-glycine-aspargine (RGD-4 C) peptide via a short PEG linker to produce particles of identical size, shape, and surface charge but with a high affinity for the α v β 3 integrins overexpressed on the tumor endothelium. Fig. 4a shows the time-dependent accumulation of targeted and untargeted plateloid particles in tumors, measured with IVM. The cumulative particle uptake was independently quantified using ICP-AES (Fig. 4b) . For untargeted particles, the level of accumulation varied from 1.2% (600× 200 nm) to 5.1% (1000 × 400 nm) to 3.2% ID/g (1800 × 600 nm). The use of RGD-4 C moieties increases tumor-specific accumulation, presenting as 4.5% (600 × 200 nm), 8.1% (1000 × 400 nm), and 6.5% ID/g (1800 × 600 nm) respectively. Interestingly, a maximum appears for the 1000 × 400 nm particles, regardless of the surface properties. The enhancement in particle accumulation with RGD-4 C addition was size-dependent, with the smallest particles showing the greatest enhancement (300% versus 50% for 600 × 200 and 1000 × 400 nm particles respectively). The 1000 × 400 nm particles exhibit the highest tumor-to-liver accumulation ratio, being equal to about 0.22 and 0.35 for untargeted and targeted plateloids respectively. This unprecedented, rapid tumoritropic accumulation was achieved using particles significantly larger than known tumor fenestration sizes.
Particle localization at the sub-organ scale
In tumors, the 1000×400 nm particles were observed to be confined within the blood vessels using both IVM and SEM imaging (Fig. 4c, top) . Particle adhesion occurred in both fenestrated and non-fenestrated regions of the tumor vasculature ( Supplementary Fig. 4) . Differently, some 600×200 nm particles (5-10% untargeted, b1% targeted) were seen outside the vascular compartment (Fig. 4c, bottom) . This is likely associated with the highly fenestrated vessels and poorly organized melanoma tissue through which the smaller plateloid particles may diffuse (Fig. 4d) .
For the major RES organs, particle association with cells of the immune system was studied using IVM, immunocytochemistry, and histological analysis ( Fig. 5 and Supplementary Figs. 5 and 6 ). Immunocytochemistry images showed that >80% of plateloid and cylindroid particles in the liver were associated with Kupffer cells (Fig. 5a,b and Supplementary Fig. 5 ). In the spleen, a similar trend was observed for the two larger plateloid particles (>70%), whereas only 50% of the 600 nm particles associated with the splenic macrophages (Fig. 5a,b) . This difference may be ascribed to the smaller size of the 600×200 nm particles, which are more prone to geometrical trapping in the splenic fenestrations, as confirmed by histological analysis (Fig. 5c) . Like the 600×200 nm plateloid particles, the 1500×200 nm cylindroid particles displayed an increased propensity to accumulate at the margins of the white pulp, as compared to their thicker counterparts which remained uniformly distributed in the red pulp ( Supplementary Fig. 5b) . Fig. 5d ,e shows SEM sections of the liver vasculature capturing different stages of the cell-particle interaction in vivo: first circulating particles firmly adhere to the surface of Kupffer cells (Fig. 5d) , then pseudopodia protrude out of the cell membrane and start to gently embrace the particles (Fig. 5d) , and eventually particles are pulled inside the cell (Fig. 5e ). In the tumor and other tissues, the percentage of particles associated with macrophages is negligibly small (Fig. 5a, Supplementary Fig. 5a ).
Mechanisms regulating preferential particle accumulation
Vascular adhesion and internalization by immune cells lining the vessel walls, such as the Kuppfer cells in the liver and the splenic macrophages, are finely regulated by the interplay between hydrodynamic forces and interfacial interactions. The latter primarily originate from the binding of receptors, expressed over the cell membrane with a density m r , to ligands, coating the particles surface with a density m l [38] . Colloidal forces may also arise at the particlecell interface but are generally much weaker than molecular interactions, especially in plasma [42] . Particle surfaces can be functionalized with ligands during synthesis or opsinized upon contact with the blood stream [43] . Nanoporous silicon particles are coated to different extents by plasma molecules which act as ligands for the CR1 and Fc receptors expressed by cells of the immune system [44] .
Following the formulation presented in Section 2, a probability of particle adhesion P a to the blood vessels can be estimated as a function of design parameters (geometry, ligand density m l , ligand-receptor affinity k a ) and biophysical conditions at the adhesion site (wall shear rate S, receptor density m r ). Fig. 6a shows the variation of P a for plateloid particles with a diameter d and for different values of the shear rate S, having fixed all the other parameters. For wall shear rates typically found in the leaky tumor vessels (low S) [8] , the P a curves exhibit a maximum at about 1000 nm. Moving from pathological to normal vessels (S >500 s
), the maximum in strength of adhesion occurs at smaller d (Supplementary Information). The existence of an optimal geometry (size and shape) maximizing vascular adhesion was previously conjectured [37] and explained as: for small particles, the interfacial area offered to the vessel walls for developing stable and strong adhesive forces is insufficient (area limited regime); on the other hand, for large particles, the hydrodynamic dislodging forces are excessively large to be balanced by interfacial adhesion interactions (force limited regime). This fine balance was recently observed experimentally for spherical beads [45] and, here, confirmed for plateloid particles (Fig. 6b) .
Using an experimental parallel plate flow chamber apparatus, the adhesive strength of untargeted plateloid particles was quantified as a function of diameter d and wall shear rate S. As shown in Fig. 6b , the 1000 nm particles adhere more avidly at all S, followed by the 1800 nm and by the 600 nm particles. As S increases, the overall number of adhering particles reduces. The strong agreement between the tumor accumulation data (Fig. 4b) , theoretical predictions (Fig. 6a) , and in vitro experiments (Fig. 6b) suggests that vascular adhesion may be dominant mechanism for their tumor accumulation. This is also supported by the IVM images presented in Fig. 4c .
The effect of the receptor density m r and ligand-receptor affinity k a on the probability of adhesion P a was also estimated and shown in Fig. 6c,d . Both parameters, although independent, characterize the specificity of molecular targeting. Consequently, the two plots in Fig. 6c,d are qualitatively similar and manifest the growth in adhesive strength with the improvement in molecular specificity (i.e. larger m r and k a ). Indeed, this is true under the idealized conditions of the in silico modeling and in vitro experiments, but it is also in agreement with the accumulation data presented for the RGD-4 C modified particles (Fig. 4b) . Again, the optimal diameter d is not significantly affected by the particles surface properties (targeted and untargeted), unless extremely large m r and k a are considered (Supplementary Information).
Particles in the liver and the spleen, unlike tumors, are taken up by immune cells lining the blood vessels in these organs (Fig. 5) . Therefore, adhesion and subsequent cell internalization should be considered in series to correctly interpret the quantitative data of Fig. 3 . In this case, particle adhesion is mediated by the CR1 and Fc receptors, which are highly expressed on the membrane of phagocytic cells (m r =10 3 and 10 5 #/μm 2 , depending on the stimulation state [46] ). Under these conditions, P a is extremely large regardless of the particle size. On the other hand, the internalization rate is affected by the particle size. In agreement with data in the literature [47] , J774.1 macrophages were found in vitro to internalize 600 × 200 nm particles faster than the 1000× 400 nm (Supplementary Fig. 7) . As a consequence, the probability of internalization -probability of adhesion ×rate of internalization -is greater for 600 ×200 nm particles compared to larger particles. This would explain the higher accumulation observed for the smaller plateloid particles in the liver and spleen (Figs. 2a and 3 ).
Conclusions
In current practice, systemically injected NPs rely on the EPR effect to preferentially accumulate within tumors. Using this delivery strategy, few NPs have achieved tumor accumulation greater than 1% ID/g. Here we demonstrate rapid (b1 h) and unprecedented (~10% ID/g) accumulation of 1000 × 400 nm plateloid particles in the tumor vasculature. The use of an EPR-independent delivery strategy allowed additional degrees of freedom over traditional tumoritropic accumulation schemes. Particle size, shape, and surface properties were all found to play an important role. In particular, 1000× 400 nm plateloid particles appeared well-suited for taking advantage of hydrodynamic forces and interfacial interactions required for efficient tumoritropic accumulation, even without the use of specific targeting ligands. Smaller plateloid particles accumulated more extensively in the liver and spleen, whereas larger plateloid particles deposited more in the lungs. Cylindroid particles exhibited a significantly lower tumor-to-liver accumulation ratio. Plateloid particles designed to recognize and adhere to diseased vessels may be employed to deliver anti-angiogenic agents directly to endothelial cells [48] , thermally ablate blood vessels supplying the tumor mass [49] , or to locally deploy cargos (drug molecules, contrast agents, NPs, etc.) to tumors characterized by small fenestrations. Furthermore, they may exploit the huge diversity of biomarkers that differentiate normal from abnormal endothelia for potentially treating and imaging a variety of pathologies, including cardiovascular, hemorrhagic, and neurodegenerative diseases [50, 51] .
Collectively, these results demonstrate that plateloid particles of the proper size, shape, and surface properties significantly enhance tumoritropic particle accumulation. Without relying on the EPR effect, they may offer notable therapeutic and imaging potential for a variety of diseases.
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